Unlocking the Immune Response in ALK-Rearranged Lung Adenocarcinoma.

IF 8.2 1区医学 Q1 IMMUNOLOGY

Cancer immunology research Pub Date : 2025-09-02 DOI:10.1158/2326-6066.CIR-25-0624

Antonio Vitale, Emilio Bria

引用次数: 0

Abstract

Anaplastic lymphoma kinase-rearranged lung adenocarcinoma (ALK+ LUAD) is currently considered an immune-resistant disease, yet underlying biological mechanisms are largely unknown. In this issue, Arai and colleagues analyzed the tumor microenvironment (TME) in ALK+ LUADs, identifying a myeloid cell-dominant immunosuppressive TME, primarily driven by IL6 secretion. Dual anti-IL6R/anti-PD-L1 treatment resulted in robust antitumor effect in mouse models, restoring immune sensitivity and tumor control. These findings highlight a promising therapeutic approach to enhance the efficacy of PD-(L)1 inhibitors by reverting TME-mediated immune resistance, reshaping the role of immunotherapy in ALK+ LUADs. See related article by Arai et al., p. 1435.

查看原文本刊更多论文

解锁alk重排肺腺癌的免疫应答。

间变性淋巴瘤激酶重排肺腺癌（ALK+ LUAD）目前被认为是一种免疫抵抗性疾病，但其潜在的生物学机制在很大程度上是未知的。在这一期中，Arai及其同事分析了ALK+ LUADs中的肿瘤微环境（tumor microenvironment， TME），发现了一种髓系细胞显性的免疫抑制TME，主要由il - 6分泌驱动。双重抗il6r /抗pd - l1治疗在小鼠模型中产生强大的抗肿瘤作用，恢复免疫敏感性和肿瘤控制。这些发现强调了一种有希望的治疗方法，即通过恢复tme介导的免疫抵抗来增强PD-(L)1抑制剂的疗效，重塑免疫治疗在ALK+ luad中的作用。参见Arai等人的相关文章，第XX页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer immunology research ONCOLOGY-IMMUNOLOGY

CiteScore

15.60

自引率

1.00%

发文量

260

期刊介绍： Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.